By Finance Pulse in Stock Market —

Sangamo Therapeutics Stock Plummets 67% After Pfizer Ends Hemophilia A Partnership

Sangamo Therapeutics Inc. stock dropped 67% as Pfizer Inc. terminated its collaboration on gene therapy for hemophilia A, impacting Sangamo's financial outlook.

An artistic depiction of a stock market chart with a downward trend, set against a backdrop of a DNA
Sangamo Therapeutics Stock Plummets 67% After Pfizer Ends Hemophilia A Partnership

Sangamo Therapeutics Inc. stock fell as much as 67% in extended trading after Pfizer Inc. ended its partnership for a gene therapy for hemophilia A.

Source